PDCD1 and cancer: Immunotherapy has revolutionized cancer treatment in the last decade; indeed, blocking the Programmed Cell Death Protein 1 (PD-1)/programmed death ligand-1 (PD-L1) axis has demonstrated great efficacy in the treatment of cancer and remains the central modality of immune targeting for monotherapy and in combination treatments.